Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22247643 | 0.90 | ABCG2 (0.54) | NTRK1PLK3ABCG2AHRMEN1 | |
| SCHEMBL7574891 | 0.83 | NTRK1 (0.44) | NTRK1PLK3ABCG2MEN1TP53 | |
| SCHEMBL7569904 | 0.83 | NTRK1 (0.44) | NTRK1PLK3AHRMEN1TP53 | |
| SCHEMBL7570047 | 0.81 | TERT (0.47) | ABCG2AHRMEN1TP53CYP3A4 | |
| SCHEMBL7571063 | 0.80 | TERT (0.49) | ABCG2MEN1CYP3A4CYP2D6MAPT | |
| SCHEMBL11768754 | 0.78 | NTRK1 (0.74) | NTRK1PLK3MEN1TP53CYP3A4 | |
| SCHEMBL30704422 | 0.78 | NTRK1 (0.74) | NTRK1PLK3MEN1TP53CYP3A4 | |
| SCHEMBL2681675 | 0.77 | ABCG2 (0.49) | NTRK1PLK3ABCG2DNMT1TP53 | |
| SCHEMBL7572043 | 0.77 | NTRK1 (0.51) | NTRK1PLK3MEN1CYP3A4MAPT | |
| SCHEMBL7568567 | 0.73 | EGFR (0.56) | NTRK1PLK3MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020182232-A9 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | L'OREAL S.A. (FR) | 2002-12-05 | — | — | US | claimed |
| US-20020012683-A1 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | HENRION JEAN-CHRISTOPHE (FR) | 2002-01-31 | — | — | US | claimed |
| EP-1134217-A2 | Cosmetic composition containing a furan-naphthoquinone derivative, use therof as dyeing agent, and derivatives | L'OREAL (FR) | 2001-09-19 | — | — | EP | claimed |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-20200231602-A1 | ORGANIC COMPOUND AND ELECTROLUMINESCENT DEVICE CONTAINING THE SAME | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2020-07-23 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2393787-B1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010091384-A2 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20020182232-A9 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | L'OREAL S.A. (FR) | 2002-12-05 | — | — | US | disclosed |
| US-20020012683-A1 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | HENRION JEAN-CHRISTOPHE (FR) | 2002-01-31 | — | — | US | disclosed |
| EP-1134217-A2 | Cosmetic composition containing a furan-naphthoquinone derivative, use therof as dyeing agent, and derivatives | L'OREAL (FR) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | NTRK1 4093/4885PLK3 4587/4885ABCG2 3187/4885 |
| US-20020012683-A1 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | CYP1B1, NDUFA2, TYR | NTRK1 4814/4885PLK3 1152/4885ABCG2 772/4885 |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | CDH1, DSC1, EPCAM | NTRK1 4509/4885PLK3 4255/4885ABCG2 4356/4885 |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | CDH1, GPR119, FABP4 | NTRK1 4709/4885PLK3 3960/4885ABCG2 3282/4885 |
| US-20200231602-A1 | ORGANIC COMPOUND AND ELECTROLUMINESCENT DEVICE CONTAINING THE SAME | OCIAD1, OCIAD2, SLCO4C1 | NTRK1 4025/4885PLK3 1411/4885ABCG2 1110/4885 |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | CDH1, ICAM1, S100A11 | NTRK1 4093/4885PLK3 4587/4885ABCG2 3187/4885 |
| US-20020182232-A9 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | TYR, SDHA, NDUFA2 | NTRK1 4797/4885PLK3 1017/4885ABCG2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.